TherapeuticsMD (TherapeuticsMD) FCF Margin % : -988.05% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. TherapeuticsMD's Free Cash Flow for the three months ended in Dec. 2023 was $-4.96 Mil. TherapeuticsMD's Revenue for the three months ended in Dec. 2023 was $0.50 Mil. Therefore, TherapeuticsMD's FCF Margin % for the quarter that ended in Dec. 2023 was -988.05%.

As of today, TherapeuticsMD's current FCF Yield % is -107.60%.

The historical rank and industry rank for TherapeuticsMD's FCF Margin % or its related term are showing as below:

TXMD' s FCF Margin % Range Over the Past 10 Years
Min: -5632.18 Med: -388.62 Max: 12.87
Current: -1772.73

During the past 13 years, the highest FCF Margin % of TherapeuticsMD was 12.87%. The lowest was -5632.18%. And the median was -388.62%.

TXMD's FCF Margin % is ranked worse than
96.98% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs TXMD: -1772.73

TherapeuticsMD FCF Margin % Historical Data

The historical data trend for TherapeuticsMD's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD FCF Margin % Chart

TherapeuticsMD Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-381.92

-248.29

-5,632.18

12.87

-1,772.73

TherapeuticsMD Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															43.99	-2,091.59	-776.20	11,373.58	-988.05

Competitive Comparison of TherapeuticsMD's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TherapeuticsMD's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's FCF Margin % distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's FCF Margin % falls into.

TherapeuticsMD FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

TherapeuticsMD's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-23.081	/	1.302
	=	-1,772.73 %

TherapeuticsMD's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.96	/	0.502
	=	-988.05 %

TherapeuticsMD FCF Margin % Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

TherapeuticsMD (TherapeuticsMD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

29TA:Germany

Address

951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431

Website

https://www.therapeuticsmd.com

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

Executives

Marlan D Walker	officer: General Counsel	951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler	officer: Principal Financial Officer	1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan	officer: CAO and VP of Finance	6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp	10 percent owner	155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman	officer: Chief Business Officer	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts	director	C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro	director
Angus C. Russell	director	C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jules A. Musing	director	9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
David Efraim Rosen	10 percent owner	155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Collins Cooper C.	director	33219 FOREST WEST DRIVE, MAGNOLIA TX 77354